Scholtysik G, Lauener H, Eichenberger E, Bürki H, Salzmann R, Müller-Schweinitzer E, Waite R
Arzneimittelforschung. 1975 Oct;25(10):1483-91.
Pharmacological properties characterizing N-amidino-2-(2,6-dichlorophenyl)acetamide hydrochloride (BS 100-141) as a centrally acting antihypertensive agent are described. Its action resembles that of clonidine in many respects but with important differences which are discussed. In DOCA-NaCl--hypertensive conscious rats, BS 100-141 lowers systemic blood pressure with oral doses of 0.3-5 mg/kg. Evidence for a central site of action is provided by the following findings. Infusion of BS 100-141 into the vertebral artery of anaesthetized dogs reduces blood pressure, the same dose being ineffective by i.v. route. Injection into the lateral cerebral ventricle of anaesthetized cats causes a marked reduction in blood pressure and heart rate, the same dose being ineffective when given i.v. The effects of intraventricular injection are inhibited by phentolamine administered by the same route. Intravenous administration of BS 100-141 induces dose-dependent reductions in the splanchnic (sympathetic) nerve activity in the cat. BS 100-141 reduces noradrenaline turnover in the brain stem of the rat as a result of central alpha-adrenoceptor stimulation. Doses which are effective in the hypertensive rat do not reduce dopamine turnover in the corpus striatum. The peripheral, direct alpha-sympathomimetic action of BS 100-141 was demonstrated by the transient increases in blood pressure observed in rats. These increases were unaffected by pretreatment with reserpine, but were antagonized by phentolamine. BS 100-141 was shown to induce contractions of isolated veins and arteries which were competitively inhibited by phentolamine. It stimulates presynaptic cardiac sympathetic alpha-adrenoceptors, thus inhibiting transmitter release to the heart. The sedative effects of BS 100-141 observed in dogs were slight compared to those of clonidine.
描述了将盐酸N-脒基-2-(2,6-二氯苯基)乙酰胺(BS 100-141)作为中枢性抗高血压药物的药理学特性。其作用在许多方面类似于可乐定,但也存在重要差异,对此进行了讨论。在DOCA-氯化钠诱导的高血压清醒大鼠中,BS 100-141口服剂量为0.3-5mg/kg时可降低全身血压。以下发现为其作用的中枢位点提供了证据。将BS 100-141注入麻醉犬的椎动脉可降低血压,相同剂量经静脉途径无效。注入麻醉猫的侧脑室可导致血压和心率显著降低,相同剂量经静脉给药无效。经相同途径给予酚妥拉明可抑制脑室内注射的作用。静脉注射BS 100-141可使猫的内脏(交感)神经活动呈剂量依赖性降低。由于中枢α-肾上腺素能受体刺激,BS 100-141可降低大鼠脑干中的去甲肾上腺素周转率。在高血压大鼠中有效的剂量不会降低纹状体中的多巴胺周转率。BS 100-141在大鼠中观察到的短暂血压升高证明了其外周直接α-拟交感神经作用。这些升高不受利血平预处理的影响,但可被酚妥拉明拮抗。已证明BS 100-141可诱导离体静脉和动脉收缩,酚妥拉明可竞争性抑制该收缩。它刺激突触前心脏交感α-肾上腺素能受体,从而抑制递质向心脏的释放。与可乐定相比,在犬中观察到的BS 100-141的镇静作用较轻。